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M
en with obesity, the metabolic
syndrome, and type 2 diabetes
have low total and free testoster-
one and low sex hormone–binding
globulin (SHBG). Conversely, the pres-
ence of low testosterone and/or SHBG
predicts the development of metabolic
syndrome and type 2 diabetes. Visceral
adiposity present in men with low testos-
terone, the metabolic syndrome, and/or
type 2 diabetes acts through proinﬂam-
matory factors. These inﬂammatory
markers contribute to vascular endothe-
lial dysfunction with adverse sequelae
such as increased cardiovascular disease
(CVD) risk and erectile dysfunction. This
review focuses on the multidirectional
impact of low testosterone associated
with obesity and the metabolic syndrome
and its effects on erectile dysfunction and
CVD risk in men with type 2 diabetes.
Whenever possible in this review, we
will cite recent reports (after 2005) and
meta-analyses.
Epidemiological studies of low
testosterone, obesity, metabolic
status, and erectile dysfunction
Epidemiological studies support a bidi-
rectional relationship between serum
testosterone and obesity as well as be-
tween testosterone and the metabolic
syndrome. Low serum total testos-
terone predicts the development of
central obesity and accumulation of
intra-abdominal fat (1–3). Also, low to-
talandfreetestosteroneandSHBGlevels
are associated with an increased risk of
developing the metabolic syndrome, in-
dependent of age and obesity (1–3).
Lowering serum T levels in older men
with prostate cancer treated with andro-
gen deprivation therapy increases body
fat mass (4). Conversely, high BMI, cen-
tral adiposity,and the metabolic syndrome
are associated with and predict low
serum total and to a lesser extent free tes-
tosterone and SHBG levels (1–3,5). Be-
cause obesity suppresses SHBG and as a
result total testosterone concentrations, al-
terations in SHBG confound the relation-
ship between testosterone and obesity.
Low total testosterone or SHBG
levels are associated with type 2 diabetes,
independent of age, race, obesity, and
criteriafordiagnosisofdiabetes(6,7).In
longitudinal studies, low serum total
and free testosterone and SHBG levels
were independent predictors of type 2
diabetes (6,8). In these studies, SHBG
levels were stronger predictors of dia-
betes than total or free testosterone.
Because type 2 diabetes is often associ-
ated with obesity, which suppresses
S H B Ga n di nt u r nt o t a lt e s t o s t e r o n e
levels,bothobesityandSHBGlevelsrep-
resent important confounding factors in
the relationship between testosterone
and type 2 diabetes. The prevalence
of low free testosterone levels is higher
in diabetic men compared with non-
diabetic men (6). However, a recent
longitudinal study found that free tes-
tosterone did not predict the develop-
ment of type 2 diabetes. In this study,
the association of total testosterone
a n do fS H B Gw i t hd i a b e t e sw a sn o ts i g -
niﬁcant after adjusting for waist circum-
ference or central obesity (9). Also, low
SHBG was found to be a strong inde-
pendent predictor of type 2 diabetes
(10,11). Finally, in prospective studies,
androgen deprivation therapy either us-
ing bilateral orchidectomy or gonado-
tropin-releasing hormone agonist in
older men with prostate cancer is asso-
ciated with an increased risk of diabetes
and CVD (12).
A number of epidemiological studies
support associations of obesity (13,14),
the metabolic syndrome (15,16), type 2
diabetes(17),andlowserumtestosterone
(18) with sexual dysfunction including
erectile dysfunction (ED) (19). These
studies highlight the complex often multi-
directional relationships among obesity,
metabolic status, low testosterone, and
ED in men.
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REVIEWPathobiology of low testosterone in
type 2 diabetes and its impact
on sexual dysfunction and CVD risk
Obesity is a proinﬂammatory state result-
ing in increased release and secretion of
proinﬂammatory cytokines and adipo-
kines, free fatty acids, and estrogens
from adipose tissue. These increases are
important risk factors that may contribute
tothedevelopmentofmetabolicsyndrome
and type 2 diabetes as well as androgen
deﬁciency (20). Visceral fat is an active
secretory tissue producing inﬂammatory
cytokines, adipokines, biochemical mod-
ulators, and other proinﬂammatory fac-
tors including interleukin (IL)-6, IL-1b,
plasminogen activator inhibitor-1, tumor
necrosis factor (TNF)-a,angiotensinogen,
vascularendothelialgrowthfactor,andse-
rumamyloidA(Fig.1).Thesefactorscon-
tributetosystemicandperipheralvascular
inﬂammation and dysfunction (21). As
shown in Fig. 1, one potential mechanism
of how visceral adiposity and inﬂamma-
tory response modulate insulin sensitivity
involves the release offree fatty acids. Free
fatty acids activate nuclear factor-kB path-
ways resulting in increased synthesis
of TNF-a. TNF-a further activates lipoly-
sis as well as increased synthesis of IL-6
andmacrophagechemoattractantprotein-1,
which increases recruitment of more mac-
rophagesandmodulatesinsulinsensitivity.
Increased production of TNF-a also en-
hances expression of adhesion molecules
in both endothelium and vascular smooth
muscle cells. IL-6 stimulates hepatic syn-
thesis of C-reactive protein, a nonspeciﬁc
marker of vascular inﬂammation. In ad-
dition, TNF-a contributes to the dys-
regulation of insulin modulation of
endothelin-1–mediated vasoconstriction
and nitric oxide–mediated vasodilation,
hence promoting vasoconstriction. Re-
lease of adipokines facilitates monocyte
adhesion and migration into the vessel
wall as well as the conversion of mono-
ctyes to macrophages.
Aromatase, the enzyme that converts
testosteronetoestradiol,ismainlylocated
in adipose tissue. Obesity is associated
with elevated estrogen in men activating
hypothalamicestrogenreceptorstriggering
inhibition of the hypothalamic-pituitary-
gonadal axis. Treatment with aromatase
inhibitors reverses the hypogonadotropic
hypogonadism associated with obesity
(22). Men with obesity and insulin resis-
tance showed attenuated Leydig cell re-
sponsiveness to exogenous gonadotropin
stimulation (23).
There are data supportive of a direct
role of testosterone in insulin sensitivity.
Acute withdrawal of testosterone in
hypogonadal men for 2 weeks reduced
insulin sensitivity without apparent
changes in body composition, suggesting
thatsexsteroidsdirectlymodulateinsulin
sensitivity(24).Othershavereportedthat
normalizing testosterone levels in older
men had favorable effects on body com-
position, which could improve insulin
sensitivity but not effects on postprandial
triglyceride metabolism (25). Recently, it
was demonstrated, using glucose clamp
studies,thattheinterplaybetweeninsulin
sensitivity, triglycerides, and sex steroids
are almost immediate and not facilitated
by changes in body composition. Con-
comitantly, increasing testosterone and
decreasing estradiol levels for 1 week
in young men improved postpran-
dial triglyceride handling, postprandial
glucose-dependent insulinotropic poly-
peptide (GIP) release, and insulin sensi-
tivity (26). These studies indicate that
interactions between low testosterone
and visceral adiposity acting through
proinﬂammatory agents (Fig. 1) result in
insulin resistance and vascular endothelial
dysfunction,whicharepotentialcausalfac-
tors for increased CVD and ED (20).
Sexual dysfunction and low
testosterone in type 2 diabetes
A national survey of sexual activity in the
U.S. found that over 60% of people with
partners were sexually active, including
individuals with diabetes (27). Similarly,
68.7% of 383 men with diabetes in the
Look Ahead Study were sexually active
(28). The clinical observation that ED
occurs at an earlier age and with greater
frequencyinmenwithdiabetescompared
with nondiabetic men is supported by
multiple population-based epidemiologi-
cal studies (27) and by surveys of clinical
practices (29). In the Look Ahead Study
(28), 49.8% of men with diabetes repor-
ted mild or moderate ED. ED was associ-
ated with age (odds ratio 1.05, 95% CI
1.01–1.10), baseline hemoglobin A1c
(1.31, 1.05–1.63), hypertension (2.41,
1.34–4.36), and the metabolic syndrome
(3.05, 1.31–7.11). There are few studies
evaluating the prevalence of reduced
libido in men with diabetes. Decreased
sexual desire is primarily affected by the
presenceofEDand bydepression.Anob-
servational study of 253 men with type 2
diabetes in Sri Lanka found that after ex-
cluding men with ED (33%), the preva-
lenceofreducedlibidowas25%(30).Ina
population-basedsurvey,prematureejacu-
lation occurred in 36.3% (95% CI 26–48)
of diabetic men and 22.9% (18–28.6) of
nondiabetic men (27). Inability to climax
wasreportedin26%ofdiabeticmenversus
Figure 1—Complex multidirectional interactions between testosterone and obesity, metabolic
syndrome, and type 2 diabetes mediated by cytokines and adipokines leading to comorbidities
such as ED and increased CVD risk. FFA, free fatty acids; GnRH, gonadotropin-releasing hor-
mone; LH, luteinizing hormone; PAI-1, plasminogen activator inhibitor-1.
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Low testosterone and type 2 diabetes15.9%ofnondiabeticmen.Prematureejac-
ulationwasreportedin40%ofthepatients
from Sri Lanka who did not have severe or
complete ED (30).
In the European Male Aging Study
database of 3,369 men between the ages
of 40 and 79 years, three sexual symp-
toms(poormorningerections,lowsexual
desire, and ED) had a syndromicrelation-
ship with decreased testosterone levels
(18).Moreover,intheEuropeanMaleAg-
ing Study, low serum testosterone was
more frequent in men with comorbidities
such as obesity, metabolic syndrome, and
type 2 diabetes. In studies from diabetes
clinics, total, bioavailable, and free testos-
terone levels were low in men with type 2
diabetes (31).When comparing testoster-
one levels in men with and without ED
and type 2 diabetes, these investigators
found signiﬁcantly lower serum bioavail-
able testosterone (P , 0.006) and free
testosterone (P , 0.027) in men with
ED, but there was no signiﬁcant differ-
enceintotaltestosteronelevels.Thelower
the serum testosterone, the greater the se-
verityofED(32).Coronaetal.(33)evalu-
ated 1,200 men with ED and reported that
16% had type 2 diabetes. Serum total tes-
tosterone levels were below the reference
range (,300 ng/dL or ,10.4 nmol/L) in
24.5% of men with diabetes versus 12.6%
of nondiabetic subjects (P , 0.0001) after
adjustment for age and BMI. In addition,
hypogonadism in men with type 2 diabe-
tes was associated with decreased sexual
desire,moresymptomsofdepression,and
lower luteinizing hormone levels.
ED in the past was ascribed to auto-
nomic neuropathy or obliterative vascu-
lar disease; more recent studies identify
endothelial dysfunction as an early ab-
normality that is potentially more amena-
ble to therapy (20). Animal studies have
demonstrated testosterone effects on
nerve structure and function, nitric oxide
synthase activity, and smooth muscle
growthanddifferentiation,whichmediate
penile erections (34). Obesity and an-
drogen deﬁciency are associated with in-
creased proinﬂammatory cytokines, which
also results in vascular endothelial dys-
function (20).
Men with type 2 diabetes can have
other causes of ED. In a study of 8,373
men with type 2 diabetes (35), ED was
associated with poor metabolic control,
smoking, alcohol, antidepressants, anti-
hypertensives,CVDmedications,andhis-
tamine 2 receptor antagonists. There are
multiple causes for low libido in the
general population and in men with
type2 diabetes inadditiontotestosterone
deﬁciency, including medications (e.g.,
serotonin reuptake inhibitors, antiandro-
gens), alcoholism, recreational drugs,
fatigue, systemic illness, depression, rela-
tionshipproblems,othersexualdysfunction
(fear of humiliation), hypoactive sexual dis-
order, and sexual aversion disorder.
The Look Ahead study reported that
weightlossandincreasedphysicalactivity
were mildly beneﬁcial in maintaining
erections or improving ED in men with
type 2 diabetes (36). Although improve-
ment in glucose control is associated with
some improvement in erectile function in
some studies, most clinicians have not
found this to be a reliable and effective
treatment for ED. The Testosterone Re-
placement in Older Men with either Met-
abolic Syndrome or Type 2 Diabetes
(TIMES 2) trial recruited hypogonadal
men with total testosterone ,318 ng/dL
(11 nmol/L) or free testosterone ,6.5
ng/dL (225 pmol/L) and either metabolic
syndromeortype2diabetes.Testosterone
treatmentimprovedlibido(37).Twometa-
analysesofmanyclinicaltrialsanalyzedthe
effectsoftestosterone ondifferent domains
of sexual function (38,39). Testosterone
treatment moderately improved the num-
berofnocturnalerections,sexualthoughts
and motivation, number of successful in-
tercourse sessions, scores of erectile func-
tion,andoverallsexualsatisfactioninmen
with baseline serum testosterone ,346
ng/dL(,12nmol/L). Theeffects oftestos-
terone on libido were more consistent
than on erectile function. Testosterone re-
placement can restore nocturnal erections
in hypogonadal men, but the effects are
greater when testosterone and a phospho-
diesterase (PDE)-5 inhibitor are adminis-
tered together.
ED in many men with diabetes is
improved by one of the PDE-5 inhibitors
when used on demand. A recently pub-
lished randomized double-blind placebo-
controlledmulticenterstudyevaluatedthe
effectiveness of daily oral dosing of tada-
laﬁl in 298 men with diabetes and ED.
Daily dosing of tadalaﬁl showed signiﬁ-
cant improvement in vaginal penetration,
completion of intercourse, and overall
treatment satisfaction (40). Testosterone
replacement therapy has been reported
to improve erections in men who did not
respond satisfactorily to a PDE-5 inhibitor
alone (41). Larger trials using testosterone
in addition to a PDE-5 inhibitor in hypo-
gonadal men with ED who have testoster-
one levels ,300 ng/dL (10.4 nmol/L) are
needed.
Low testosterone, CVD risks, and
type 2 diabetes
There is increasing evidence from multi-
ple studies after adjustment of confound-
ing variables that low serum testosterone
is associated with an increase in all-cause
mortality that is independent of the met-
abolic syndrome and diabetes (42–45)
(Table 1). Low testosterone predicted
the increased risk of CVD independent
of age, obesity, hyperlipidemia, and
lifestyle in men with or without type
2 diabetes (43–45). In patients with
CVD, excess mortality was noted in the
testosterone-deﬁcient men compared with
men with normal serum testosterone con-
centrations (46) (Table 1). Testosterone
deﬁciency and CVD are both associated
with visceral fat accumulation, metabolic
Table 1—Low testosterone is associated with increased mortality in older men
Study design n Follow-up (years) Mortality Hazard ratio (95% CI) Recent studies
Retrospective 858 8 All-cause 1.88 (1.34–2.63)* Shores et al. (42)
Prospective 794 20 All-cause and CVD
1.40 (1.14–1.71)*
1.38 (1.02–1.85)* Laughlin et al. (45)
Prospective 2,314 10 All-cause and CVD 2.29 (1.60–3.26)* Khaw et al. (43)
Prospective 1,954 7.2 All-cause and CVD 2.32 (1.38–3.89)* Haring et al. (44)
Prospective 930 6.9 All-cause and CVD in
men with CVD
2.27 (1.45–3.60)* Malkin et al. (46)
*On the basis of recent publications in which the number of subject is .500 and age of the subjects is .60 years.
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Wang and Associatessyndrome, type 2 diabetes, increased in-
ﬂammatory cytokines, hyperlipidemia,
and abnormalities of coagulation (47).
In intervention studies on a small
number of subjects, administration of tes-
tosterone caused coronary artery dilation,
decreased myocardial ischemia, and im-
proved angina during stress tests (48,49).
Others suggest that testosterone may im-
prove chronic heart failure (50,51). In a
recent study, Testosterone in Older Men
with Mobility Limitations (TOM), the
older men had multiple comorbidities in-
cluding obesity, hypertension, diabetes,
andhyperlipidemia,theapplicationofrel-
ativelyhighdosesoftransdermaltestoster-
one gel was associated with signiﬁcantly
higher CVD event rates than in patients
treated with placebo gel (52). An increase
in CVD event rate was not observed in
another study of frail elderly men treated
with lower doses of transdermal testoster-
one gel compared with the placebo-treated
men (53). The adverse CVD events in the
TOM trial suggest that monitoring for car-
diovascular adverse events is essential in a
testosterone intervention study of older
men with or without type 2 diabetes and
we need a better understanding of testos-
terone effects on coagulation.
Clinical studies of testosterone
replacement in men with obesity,
metabolic syndrome, type 2 diabetes,
and low testosterone concentrations
The major goal of testosterone replace-
ment therapy is to increase serum testos-
terone concentrations to physiological
concentrations with the purpose of re-
solvingsymptomsandbiologicalsequelae
of hypogonadism. The advent of new
modes of testosterone delivery such as
transdermal testosterone gels and depot
intramuscular testosterone undecanoate
injections have made physiological re-
placementpossible.Testosteronereplace-
mentinthehypogonadalmanwithtype2
diabetes and/or metabolic syndrome
should aim to have beneﬁcial effects on
multiple outcomes including sexual
health; general well-being; body compo-
sition; and reducing CVD risk factors,
includingcentraladiposity,glycemiccon-
trol, and atherogenic lipid proﬁle.
Evidencefromseveralstudies(Table2)
demonstrated that testosterone promotes
insulin sensitivity in hypogonadal men
with and without type 2 diabetes. Mårin
et al. (54) were the ﬁrst to report that tes-
tosterone improved insulin sensitivity as-
sessed by euglycemic clamp studies in
obesemenwhilereducingcentraladipos-
ity. More recently, a randomized double-
blind crossover trial demonstrated a
signiﬁcant reduction in insulin resistance
in hypogonadal men with type 2 diabetes
(55). This ﬁnding was conﬁrmed in three
furtherstudiesinmenwithmetabolicsyn-
drome and/or type 2 diabetes (37,56,57).
Hypogonadismwitheitherofthesecondi-
tions was the major inclusion criterion.
Subjects were not selected for poor dia-
betic control (Table 2). Even so, three
studies reported decreases in HbA1c levels
in the men with diabetes (37,55,56).
Insulin resistance commonly occurs in
chronicheartfailure,andithasbeenshown
to improve with testosterone replacement
therapy (58). As discussed above, the
mechanisms by which testosterone im-
proves insulin sensitivity is multifactorial
Table 2—Randomized trials of testosterone replacement in hypogonadal men with metabolic syndrome or type 2 diabetes
Study Kapoor et al. (55) Heufelder et al. (56) Kalinchenko et al. (57) Jones et al.* (37)
Subjects Type 2 diabetes New type 2 diabetes/
metabolic syndrome
Type 2 diabetes/
metabolic syndrome
Type 2 diabetes/
metabolic syndrome
Study design RCT-c NRCT RCT-p RCT-p
n 24 32 184 220
Duration (months) 3 12 6 6/12*
Medications for diabetes Diet, oral, insulin Naive Diet, oral Diet, oral
Baseline serum testosterone (nmol/L) #8.6 #10.5 #6.7 #10.2
Testosterone formulation TES injections
(200 mg/2 weeks)
Testosterone gel
(50 mg/day)
TU depot injections Testosterone gel
(40–80 mg/day)
Treatment effects (changes)
HOMA-IR 21.7 20.9 21.49 20.54
Fasting glucose (nmol/L) 21.6 20.3 (AS) ↔ 20.42 (AS)
Fasting insulin (mIU/mL) ↔ ↓ ↔ ↓(AS)
HbA1c 20.37 20.80 ND ↔ [20.45]†
Total cholesterol (nmol/L) 20.4 ND ↔↔ [20.13]
LDL cholesterol (nmol/L) ↔ ND ↔↔ ‡
HDL cholesterol (nmol/L) ↔ ↑§ ↔ 20.049‡
Triglycerides ↔ ↓ ↔↔
Lipoprotein a ND ND ND ↓
BMI ↔↔ ↔ ↔
Waist circumference ↓↓ ↓ ↔
% Body fat ND ND ND ↔
Blood pressure ↔ ↓| ND ↔
↔,No signiﬁcant change;↑,signiﬁcant increase;↓,signiﬁcantdecrease;AS, approachingsigniﬁcance(P =0.05–0.07); ND,notdone; NRCT, randomizedopenlabel,
not placebo-controlled parallel trial; RCT-c, randomized placebo-controlled crossover; RCT-p, randomized placebo-controlled parallel; TES, mixed testosterone
esters;TU,testosteroneundecanoatedepotinjectionsaftertheﬁrstinjectionfollowedbyanotherinjectionat6weeksandtheninjectionsevery12weeks.Testosterone
gel was dose-adjusted to give total testosterone level .17 nmol/L. *The study by Jones et al. (TIMES2) had no medication changes in the ﬁrst 6 months unless
overriding clinical needs, but medication changes were allowed in the second 6 months for ethical reasons (intention-to-treat group, modiﬁed per protocol group
where no changes in medications occurred; data not shown). †Signiﬁcant difference compared with placebo observed after 9 months, but result may be confounded
by allowed medication changes. ‡Metabolic syndrome subgroup showed signiﬁcant changes in total cholesterol (20.34 mmol/L), LDL cholesterol (20.21 mmol/L),
and HDL cholesterol (20.058 mmol/L). §No ﬁgure quoted. |Diastolic blood pressure only.
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Low testosterone and type 2 diabetesand likely to be due to a combination of
testosterone effects on liver, muscle, and
adipose tissues and by reducing the pro-
duction of inﬂammatory cytokines (e.g.,
TNF-a, IL-1b, and IL-6), which cause in-
sulin resistance (Fig. 1) (59).
It is well known that testosterone
replacement reduces body fat mass and
waist circumference in hypogonadal men
with and without obesity (54,59). In men
with the metabolic syndrome and/or type
2 diabetes, a decrease in central adiposity
w a so b s e r v e di na l lb u to n es t u d yw i t h
testosterone treatment (55–57). BMI im-
proved in only one trial (56) and body fat
decreased in another in those men who
did not have changes in medications
that affect body weight (37). Leptin levels
correlate with body fat content and have
been shown to decrease with testosterone
replacement in type 2 diabetes and the
metabolic syndrome (57,60). The effect
of testosterone on lipid proﬁle was inves-
tigated in several studies including those
on coronary heart disease, metabolic syn-
drome, anddiabetes (59).Themajorityof
studies have found that testosterone ther-
apy resultsin a smallbut signiﬁcant fallin
total cholesterol and in some LDL choles-
terol (37,55,59) (Table 2). HDL choles-
terol may fall, rise, or remain unchanged
(59). There is some evidence that after an
initial decrease, HDL cholesterol levels
then return to baseline (37). Most reports
found no change in triglycerides. Lipo-
proteina,whichhasthestrongestpositive
correlation with premature coronary
heart disease than any other component
of the lipid proﬁle, was found to fall sig-
niﬁcantly after testosterone treatment of
men with the metabolic syndrome and/
or type 2 diabetes (37).
Current evidence, albeit from mainly
small-scale studies, does demonstrate
some beneﬁcial effects of testosterone on
important CVD risk factors, which in-
cludeinsulinresistance,glycemiccontrol,
lipid proﬁle, central adiposity, bodycom-
position, and inﬂammatory state in hypo-
gonadalmenwithtype2diabetes,aswellas
sexual health. None of these clinical trials
reported any adverse effects on blood pres-
sure, cardiovascular events, or mortality.
Conclusions
The multidirectional interrelationships
between serum testosterone and SHBG
with obesity, metabolic syndrome, and
type 2 diabetes are complex. Obesity is
accompanied by increased adipokines,
cytokines, and other proinﬂammatory
factor production from adipocytes and
macrophages mainly in visceral fat. These
factorsmayalterinsulinresponsivenessin
fat, liver, muscle, and endothelial func-
tion resulting in metabolic syndrome,
type 2 diabetes, ED, and CVD. Many
menwith type2diabetes,especiallythose
who are obese, have low serum total
testosteroneand SHBGlevels. Small-scale
studies of testosterone treatment in men
with metabolic syndrome or type 2 di-
abetes and borderline low or normal
testosterone levels showed small im-
provement in glycemic control. Many of
these studies in men with type 2 diabetes
are associated with confounders, includ-
ing changes in medications for diabetes.
More randomized placebo-controlled in-
terventional trials of testosterone treat-
ment in testosterone-deﬁcient men with
the metabolic syndrome and poorly con-
trolled type 2 diabetes are needed to
evaluate the putative role of testosterone
in the interruption of the vicious cycle
contributed by metabolic imbalances. At
present, it is important for the clinician to
recognize that low testosterone and sex-
ual dysfunction are commonly found in
patients with obesity, metabolic syn-
drome, and type 2 diabetes. Testosterone
replacement, in addition to diet, exercise,
glycemic control, and PDE-5 inhibitors,
should be considered in symptomatic
hypogonadal men with type 2 diabetes
andserumtestosteronebelowthereference
range. During testosterone treatment,
monitoring should include assessment of
improvement of symptoms, glycemic con-
trol, lipid levels, hematocrit, and potential
adverseeffectsincludingCVDandprostate
diseases in older men.
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